Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks ...

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune response, according to updated results of a phase 1 trial. Injection site ...

researchers have developed a method to assess which patients with metastatic triple-negative breast cancer could benefit from ...

While triple-negative breast cancer may be more aggressive than hormone receptor-positive breast cancer, it may also be more curable. Family history is a risk factor for breast cancer. A number of ...

Jennifer Griffin was diagnosed with stage 3 triple-negative breast cancer in 2009, and underwent chemotherapy, a double mastectomy, and radiation for treatment. She was declared in remission in 2010.

Izalontamab is under clinical development by Systimmune and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer ...